Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
For those who worry about these things, there is a mini-review in the most recent issue of BJU International on the association between coffee consumption and risk for prostate cancer.
Filed under: Prevention | Tagged: coffee, risk | Leave a Comment »
There is an interesting new paper forthcoming in the Journal of Urology in which the research team describes how the addition of data from genetic profiling is able to improve the accuracy of the Kattan pre-treatment nomogram specifically in men believed to have localized prostate cancer at the time of diagnosis.
Filed under: Diagnosis, Management, Risk, Uncategorized | Tagged: gene, Kattan, nomogram, pre-treatment, prognosis | Leave a Comment »
In early 2009 the European Randomized Study of Screening for Prostate Cancer (ESRPC) reported a reduction of 20 percent in prostate cancer-specific mortality in a screened cohort of men aged between 55 and 74 years of age — as opposed to an unscreened cohort with the same age constraints.
Filed under: Diagnosis, Risk | Tagged: age, mortality, outcomes, PSA, risk, screening | 8 Comments »
An editorial commentary printed in today’s New York Times is focused on an estimate by the US Congressional Budget Office that “an astonishing half or more of the increased spending for health care in recent decades is due to technological, surgical and clinical advances.”
Filed under: Diagnosis, Risk | Tagged: Diagnosis, outcome, PSA, risk, screening, test | 3 Comments »
The current report offers a revised and updated commentary on the paper by Abd et al., first referred to yesterday on this blog. We have now had the opportunity to read the entire paper. While it does not change the general tenor of our prior comments, it is useful to make sure one has all [...]
Filed under: Diagnosis | Tagged: biopsy, cores, Diagnosis, number, positive, veteran | Leave a Comment »
According to a media release from a division of Johnson & Johnson earlier today, an independent data monitoring committee has recommended that patients in the placebo arm of a Phase III trial of abiraterone acetate be offered treatment with abiraterone following unblinding of study data.
Filed under: Drugs in development | Tagged: abiraterone, early access, trial | 8 Comments »
Back in the 1990s, it became customary to carry out prostate cancer biopsies under transrectal ultrasound (TRUS) guidance using the so-called “sextant” approach, under which six preplanned biopsy cores were taken from each of six specific areas of the prostate.
Filed under: Diagnosis | Tagged: biopsy, cores, number, outcome | 1 Comment »
The prostate cancer research team at Memorial Sloan-Kettering Cancer Center (MSKCC) has proposed and tested a new means for categorizing the amount of “damage” to the cavernous nerves as a method of predicting preservation of erectile function after radical prostatectomy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: erectile function, nerve-sparing, NSS, outcome, score | 1 Comment »
Intraductal carcinoma of the prostate is occasionally (but rarely) diagnosed on prostate biopsy and is more commonly evident in radical prostatectomy specimens. Basically, this is a type of prostate cancer in which malignant epithelial cells fill large acini and prostatic ducts, and has other specific pathological features.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: biopsy, carcinoma, intraductal, ouctome | 4 Comments »
For many years a relatively small group of specialists have argued that “enhanced” types of transrectal ultrasound technology (most specifically inclusive of color Döppler ultrasound) have a greater ability to identify possible signs of prostate cancer than traditional “gray-scale” ultrasound.
Filed under: Diagnosis | Tagged: biopsy, detection, Diagnosis, ultrasound | 4 Comments »
Bafetinib (previously known as INNO-406) is a protein kinase inhibitor that targets two different enzymes. The newly announced trial is designed to investigate the potential of bafetinib in the treatment of men with castration-resistant prostate cancer (CRPC) who have progressive disease after treatment with at least one course of chemotherapy.
Filed under: Drugs in development | Tagged: bafetinib, castration-resistant, CRPC | Leave a Comment »
We know from prior research that mice that have prostate cancer and are fed a no-carbohydrate ketogenic diet (NCKD) have smaller prostate cancer tumors and live longer than mice that are fed the mouse equivalent of a standard “Western” diet.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: carbohydrate, diet, fat, ketogenic, NCKD | Leave a Comment »
It will hardly come as a shock to the informed reader that the patients who are greatest risk for recurrence of their prostate cancer at > 5 years after a radical prostatectomy (RP) are those with high-risk disease at the time of surgery.
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: long-term, outcome, radical prostatectomy | Leave a Comment »
The drug company that is hoping to get approval to market abiraterone acetate launched a new web site this week. It doesn’t say a word about abiraterone, but …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: abiraterone | 2 Comments »
In March 2009, Thompson et al. published data from the SWOG 8794 trial showing that adjuvant radiation therapy immediately post-surgery significantly improved the oncologic outcomes of men with pathologic T3N0M0 prostate cancer compared to later salvage radiation, but
Filed under: Management, Treatment | Tagged: adjuvant, post-surgery, radiation, salvage, surgical margins, T3 disease | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site